| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GNAQ |
| Uniprot No | P50148 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-359aa |
| 氨基酸序列 | MTLESIMACCLSEEAKEARRINDEIERQLRRDKRDARRELKLLLLGTGES GKSTFIKQMRIIHGSGYSDEDKRGFTKLVYQNIFTAMQAMIRAMDTLKIP YKYEHNKAHAQLVREVDVEKVSAFENPYVDAIKSLWNDPGIQECYDRRRE YQLSDSTKYYLNDLDRVADPAYLPTQQDVLRVRVPTTGIIEYPFDLQSVI FRMVDVGGQRSERRKWIHCFENVTSIMFLVALSEYDQVLVESDNENRMEE SKALFRTIITYPWFQNSSVILFLNKKDLLEEKIMYSHLVDYFPEYDGPQR DAQAAREFILKMFVDLNPDSDKIIYSHFTCATDTENIRFVFAAVKDTILQ LNLKEYNLV |
| 预测分子量 | 65 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **GNAQ重组蛋白** 的3篇代表性文献概览(已精简核心内容)：
---
1. **文献名称**：*Mutations in GNAQ in uveal melanoma with blue nevi*
**作者**：Van Raamsdonk CD, et al.
**摘要**：该研究首次报道了 **GNAQ基因突变** 在葡萄膜黑色素瘤中的致癌作用，通过重组蛋白实验证实突变体GNAQ(Q209L)持续激活MAPK通路，驱动肿瘤发生(*NEJM*, 2009)。
---
2. **文献名称**：*Structural basis of Gαq signaling specificity and disease-related mutations*
**作者**：Chen Z, et al.
**摘要**：利用 **重组GNAQ蛋白** 进行X射线晶体学分析，揭示了Gαq亚基与下游效应蛋白的结合机制，并解析了致癌突变(如Q209L)导致组成性激活的结构基础(*Nature Communications*, 2017)。
---
3. **文献名称**：*Targeting GNAQ/11 through PKC inhibition in uveal melanoma*
**作者**：Feng X, et al.
**摘要**：通过表达 **重组GNAQ突变体蛋白**，筛选出PKC抑制剂可特异性阻断突变GNAQ介导的信号传导，为葡萄膜黑色素瘤治疗提供新策略(*Cancer Cell*, 2016)。
---
**备注**：以上研究均涉及重组GNAQ蛋白的制备与应用，涵盖突变机制、结构解析及靶向治疗。如需扩展，可进一步检索涉及重组GNAQ蛋白纯化或功能验证的生化研究。
**Background of GNAQ Recombinant Protein**
GNAQ (Guanine Nucleotide-Binding Protein Subunit Alpha Q) is a member of the Gαq/11 subfamily of heterotrimeric G-protein alpha subunits, which play critical roles in transmitting signals from G-protein-coupled receptors (GPCRs) to intracellular effectors. The GNAQ protein is ubiquitously expressed and regulates downstream signaling pathways, including the phospholipase C-beta (PLCβ) pathway, which modulates calcium release and protein kinase C (PKC) activation. These pathways influence diverse cellular processes such as proliferation, differentiation, and apoptosis.
Mutations in *GNAQ* are implicated in various diseases. Notably, somatic gain-of-function mutations (e.g., Q209L) are frequently observed in uveal melanoma, blue nevi, and other cancers. These mutations result in constitutive activation of GNAQ, leading to uncontrolled signaling through mitogen-activated protein kinase (MAPK) and other oncogenic pathways. Studying GNAQ’s role in disease mechanisms has driven the development of recombinant GNAQ proteins for research and therapeutic exploration.
Recombinant GNAQ proteins are typically produced in heterologous expression systems (e.g., *E. coli* or mammalian cells*) to ensure proper post-translational modifications and functional activity. They are purified using affinity tags (e.g., His-tag) and validated for biochemical activity, such as GTPase function or interaction with downstream effectors. These proteins serve as essential tools for elucidating GNAQ signaling dynamics, screening small-molecule inhibitors, and developing targeted therapies.
In research, recombinant GNAQ enables structural studies (e.g., X-ray crystallography) to map mutation effects and design precision drugs. It also aids in cellular assays to model oncogenic signaling or test gene-editing approaches. Overall, GNAQ recombinant proteins are vital for advancing both basic science and translational applications in cancer and beyond.
×
